Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome

Boehringer Ingelheim9,984 enrolled

Overview

Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.

Study Type

OBSERVATIONAL

Enrollment

9,984

Conditions

Arthritis, Rheumatoid

Interventions

MeloxicamDRUG

Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolacDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Indications according to the package insert of the prescribed NSAID Exclusion Criteria: * There is no exclusion criterion, because this Post Marketing Study is an observational study

Outcomes

Primary Outcomes

Incidence for adverse event of gastrointestinal disorder

Time frame: up to 6 months

Secondary Outcomes

Incidence for adverse drug reaction of gastrointestinal disorder

Time frame: up to 6 months

Incidence of adverse events

Time frame: up to 6 months

Incidence of adverse drug reactions

Time frame: up to 6 months

Incidence of serious adverse events

Time frame: up to 6 months

Incidence for adverse events Perforation, Ulcer and Bleeding (PUB) in the upper gastrointestinal tract

Time frame: up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.